Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is a promising company in the gene therapy space, backed by a robust pipeline of 13 programs, strong biomarker data, and promising preclinical studies showing a correlation between biomarker data and clinical benefit. However, the recent out-licensing of two lead programs and the challenging financing environment in the biotech industry may pose risks to the company's development plans. This may impact the ability to move their lead program, PBFT02, into a confirmatory trial in the near term.

Bears say

Passage Bio is facing significant regulatory hurdles with their lead program PBFT02 for frontotemporal dementia (FTD), as seen with the recent discontinuation of a similar program by Eli Lilly. This could result in a large investment for Pharmas and potentially hinder the development and advancement of their pipeline. Additionally, the company's total cash of $46.3M and projected cash per share at YE26 raises concerns about future financing and their ability to sustain operations. This, combined with the general risks faced by the biotech industry, leads to a negative outlook on Passage Bio's stock.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.